The Karma system is currently undergoing maintenance (Monday, January 29, 2018).
The maintenance period has been extended to 8PM EST.
Karma Credits will not be available for redeeming during maintenance.
Patient-Centered Innovations, Education and Technology for Cancer Care, Cancer Survivorship and Cancer Research
JMIR Cancer (JC) is a Pubmed-indexed, peer-reviewed journal with a focus on education, innovation and technology in cancer care, cancer survivorship and cancer research, as well as in participatory and patient-centred approaches. A sister journal of the Journal of Medical Internet Research (JMIR), a leading eHealth journal (Impact Factor 2017: 4.671), the scope of JC is broader and includes non-Internet approaches to improve cancer care and cancer research.
We invite submission of original research, viewpoints, reviews, tutorials, case studies, and non-conventional articles (e.g. open patient education material and software resources that are not yet evaluated but free for others to use/implement).
In our "Patients' Corner", we invite patients and survivors to submit short essays and viewpoints on all aspects of cancer, but in particular suggestions on how to improve the health care system, and suggestions for new technologies, applications and approaches (no article processing fees).
JC is open access and all articles are published under a Creative Commons Attribution license. JC has been accepted for indexing in PubMed Central and Pubmed.
Right click to copy or hit: ctrl+c (cmd+c on mac)
This manuscript needs more reviewersPeer-Review Me
The DNA methyltransferase inhibitors (DNMTi) are the greatest effective epigenetic drugs to date and are still the most widely used as epigenetic modulators, even though their application for oncologi...
The DNA methyltransferase inhibitors (DNMTi) are the greatest effective epigenetic drugs to date and are still the most widely used as epigenetic modulators, even though their application for oncological diseases is restricted by their relative toxicity and poor chemical stability. Unfortunately, there is no a review related to the studies related to different DNMTi and breast cancer treatment. This review the DNMTi impact on breast cancer therapy, through the available literature we will run a systematic review. The specific review questions to be addressed are: (1) what constitutes current best practice in relation DNMTi interventions for hospitalized breast cancer patients? (2) What are the indications for, and the safety and effectiveness of, the range of interventions available? This protocol represented the methods including: inclusion criteria search strategy, Selection of studies, Quality assessment, and the last but not the least Statistical analysis and data synthesis which will be passed throughout of our research.
Background: There is limited knowledge regarding the potential benefits of physical activity in patients with metastatic breast cancer. Objective: The ABLE Trial aimed to assess the feasibility of a p...
Background: There is limited knowledge regarding the potential benefits of physical activity in patients with metastatic breast cancer. Objective: The ABLE Trial aimed to assess the feasibility of a physical activity intervention in women with metastatic breast cancer and explore the effects of physical activity on functional, psychological, and clinical parameters. Methods: The ABLE Trial was a single-arm, six-month intervention study with home-based, unsupervised, and personalized walking program using an activity tracker. At baseline and six months, we assessed anthropometrics, functional fitness, physical activity level, sedentary, quality of life, fatigue, and tumour progression. Paired proportions were compared using the McNemar’s test and changes of parameters during the intervention were analyzed using the Wilcoxon signed-rank test, Mann Whitney test, and Spearman's rank correlations. Results: Overall, 49 participants (mean age, 55 years; recruitment rate, 94%) were enrolled and 96% adhered to the exercise prescription (attrition 2%). Statistically significant improvements in the 6-minute walking distance (+7%, p<.001) and isometric quadriceps strength (+22%, p<.001), and decreases in body mass index (-2.5%, p=.03) and hip circumference (-4.0%, p<.001) were observed at six months. Quality of life remained stable and a non-statistically significant decrease (-16%, p=.07) in fatigue was observed. Conclusions: The high recruitment and adherence rates suggest the willingness of patients with metastatic breast cancer to participate in a physical activity program. The beneficial outcomes regarding physical fitness and anthropometry of this unsupervised physical activity program may encourage these patients to maintain a physically active lifestyle. Future randomized controlled trials with larger sample size are warranted. Clinical Trial: NCT03148886